Fig. 2

The activities of LPPC with peptides-loaded HLA-A2 molecules and anti-CD28 mAb in vivo. A The picture illustrated how to evaluate LPPC/HLA/Ab complexes could stimulate the mice immunity against YML antigens and TC1/AAD cells in vivo. B-G The mice with different treatments were determined the immunomodulation efficiency of immuno-LPPC complexes, which included cell proliferation rate and cytokines expressions (IL-2, IFN-γ, TNF-α, IL-4, and IL-10). A significant difference was indicated by * (P < 0.05) and ** (P < 0.01). Data were expressed as the mean ± SD (N = 6). H The splenocytes from the mice which were immunized with different treatments incubated with YML-presented TC1/AAD cells. MTT assay was evaluated the cytotoxicity of mice splenocytes. Significant differences were found for the LPPC/HLA/CD28 group compared with the LPPC group (N = 6, *: P < 0.05, **: P < 0.01)